Momenta Pharmaceuticals Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Momenta Pharmaceuticals Inc.

MNTA 52.48

0.0%

Oct 2 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (2516)	5/15/2011 2:17:02 PM
From: tuck	1 Recommendation of 3027

More color on the FDA's current thinking regarding biosimilars (hat tip to jq1234 of IHub): biocentury.com "Behrman, who is associate director for medical policy in the Center for Drug Evaluation and Research, said the agency will spell out in a series of guidance documents how it will implement a two-step approach to reviewing biosimilars. At least one guidance will be released before year end, she said . . ." If only the first in a series of guidance documents is going to make it out this year, that suggests it will be well into next year, at best, before the FDA's thought process on this subject is completely known. This in turn continues to suggest to me that a FOB partnership for MNTA is not coming this year. That said, the process as we currently know it would appear to play to MNTA's strengths. Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next